Research Analysts’ Upgrades for November 20th (AGIO, APO, CMCX, DSGN, FCNCA, GAW, HSBC, JKHY, MAGN, MMC)

Research Analysts’ upgrades for Thursday, November 20th:

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Leerink Partners from a market perform rating to an outperform rating. Leerink Partners currently has $34.00 target price on the stock, down from their previous target price of $40.00.

Apollo Global Management (NYSE:APO) was upgraded by analysts at Morgan Stanley from an equal weight rating to an overweight rating. They currently have $180.00 target price on the stock, up from their previous target price of $151.00.

CMC Markets (LON:CMCX) was upgraded by analysts at Shore Capital to a buy rating. Shore Capital currently has GBX 330 price target on the stock, up from their previous price target of GBX 280.

Design Therapeutics (NASDAQ:DSGN) was upgraded by analysts at Royal Bank Of Canada from a sector perform rating to an outperform rating. The firm currently has $13.00 price target on the stock, up from their previous price target of $6.00.

First Citizens BancShares (NASDAQ:FCNCA) was upgraded by analysts at Raymond James Financial, Inc. from an outperform rating to a strong-buy rating. They currently have $2,200.00 target price on the stock, up from their previous target price of $2,100.00.

Games Workshop Group (LON:GAW) was upgraded by analysts at Peel Hunt to a buy rating. Peel Hunt currently has £180 target price on the stock, up from their previous target price of £165.

HSBC (NYSE:HSBC) was upgraded by analysts at Erste Group Bank AG from a hold rating to a buy rating.

Jack Henry & Associates (NASDAQ:JKHY) was upgraded by analysts at Raymond James Financial, Inc. from a market perform rating to a strong-buy rating. They currently have $198.00 target price on the stock.

Magnera (NYSE:MAGN) was upgraded by analysts at Vertical Research from a hold rating to a buy rating. The firm currently has $15.00 price target on the stock.

Marsh & McLennan Companies (NYSE:MMC) was upgraded by analysts at Barclays PLC from an equal weight rating to an overweight rating. Barclays PLC currently has $206.00 price target on the stock, down from their previous price target of $221.00.

Nasdaq (NASDAQ:NDAQ) was upgraded by analysts at Morgan Stanley from an equal weight rating to an overweight rating. Morgan Stanley currently has $110.00 price target on the stock, up from their previous price target of $97.00.

Parsons (NYSE:PSN) was upgraded by analysts at William Blair from a market perform rating to an outperform rating.

Avita Medical (NASDAQ:RCEL) was upgraded by analysts at BTIG Research from a sell rating to a neutral rating.